Structuring research in times of crisis

Structuring research in times of crisis

The emergence and spread of infectious pathogens such as SARS-CoV2 calls for new responses, in line with the urgency of epidemic crises. True to its mission to react rapidly in the event of an infectious disease emergence and from the very first days of an epidemic, REACTing was mobilized as early as January 2020 to deal with the COVID-19 epidemic. Several multidisciplinary and cross-disciplinary structures have been set up to coordinate and structure French research, both in laboratories and in the administration.

As early as January 2020, the REACTing consortium set up a COVID-19 Scientific Advisory Board (SAB) bringing together experts from various institutions and disciplines, which became the ANRS | EID COVID-19 SAB in 2021.
The ANRS | EID COVID-19 SAB has been mandated by the French authorities to define the national research priorities on COVID.
The SAB is also mandated to provide advice to the CAPNET on the relevance of research protocoles.

The SAB is chaired by Pr Jean-François Delfraissy.


→ To learn more : click here

The CAPNET is a consultative Committee composed of different actors of research involving the human person whose mission is to regulate clinical and preclinical studies on Covid-19 in order to accelerate those that fall within the scope of national priorities and are the most promising.

It relies on the scientific and methodological evaluations carried out by ANRS | EID COVID-19 Scientific Advisory Board, to deliver a label of "National Research Priority" to studies with a high potential impact.

ANRS | Emerging Infectious Diseases has the status of a contributing member within CAPNET and acts as its scientific secretariat.


→ To learn more : click here

The French Scientific Advisory Committee for COVID-19 vaccines has been mandated by the French Government to provide with high-level scientific expertise on COVID 19 vaccine candidates.

As thus the Committee is commissioned to:

  • Keep the French Government aware of the evolving COVID-19 vaccine landscape
  • Provide advice to the Government on the relevance of clinical trials proposed for implementation through the COVIREIVAC  network
  • Provide up-to-date scientific advice to the Government on the various vaccines considered by France/the European Commission for purchase and reservation

The Committee is chaired by Marie Paule Kieny, Immunologist – Inserm.


→ To learn more : click here